Pfiz­er shares pos­i­tive Phase 3 re­sults in breast can­cer sub­set 

Pfiz­er touts Ibrance’s sta­tus as a stan­dard of care in HR-pos­i­tive, HER2-neg­a­tive metasta­t­ic breast can­cer. Now the com­pa­ny wants to ex­pand to HER2-pos­i­tive pa­tients. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER